New Metric for Assessing Quality and Managing Risk in Contract Partner Selection
As the pharmaceutical supply chain becomes more and more complex with increasing numbers of outsourced partners supporting the production of innovator companies’ drugs, it has become more important to question how quality should be assessed when searching for contract partners
This paper presents the 483 Issuance Rate as a key "new" quality metric during the contract partner selection process. The paper also offers a discussion of recent regulatory inspection trends and the relationship of these trends to the contract partner selection process.
After completing the registration form you will have access to download the white paper in PDF format.